Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 361 participants.

Also called NCT02103959

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 361 participants (enrolled count) (from the registry)
Sponsor
Ischemix, LLC (from the registry)
Registry
  • NCT NCT02103959
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02103959. Randomized; quadruple masking; primary purpose prevention. Start 2014-06 (registry gives no type); primary completion 2015-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography
Acronym
CARIN
Condition
Non STEMI
Condition
Unstable Angina
Intervention (Drug)
CMX-2043
Intervention (Drug)
Placebo comparator
Lead sponsor
Ischemix, LLC (class: industry)

Record details

Record id
cardio:ct-nct02103959
Content hash
aa064529ab8421c526658a2f079391830b8315ad7b451b8879f96cbe36fe11c0